PURPOSE: Although the majority of patients with relapsed or refractory large B-cell lymphoma respond to axicabtagene ciloleucel (axi-cel), only a minority of patients have durable remissions. This prospective multicenter study explored the prognostic value of circulating tumor DNA (ctDNA) before and after standard-of-care axi-cel for predicting patient outcomes. METHODS: Lymphoma-specific variable, diversity, and joining gene segments (VDJ) clonotype ctDNA sequences were frequently monitored via next-generation sequencing from the time of starting lymphodepleting chemotherapy until progression or 1 year after axi-cel infusion. We assessed the prognostic value of ctDNA to predict outcomes and axi-cel-related toxicity. RESULTS: A tumor clonotype was successfully detected in 69 of 72 (96%) enrolled patients. Higher pretreatment ctDNA concentrations were associated with progression after axi-cel infusion and developing cytokine release syndrome and/or immune effector cell-associated neurotoxicity syndrome. Twenty-three of 33 (70%) durably responding patients versus 4 of 31 (13%) progressing patients demonstrated nondetectable ctDNA 1 week after axi-cel infusion (P < .0001). At day 28, patients with detectable ctDNA compared with those with undetectable ctDNA had a median progression-free survival and OS of 3 months versus not reached (P < .0001) and 19 months versus not reached (P = .0080), respectively. In patients with a radiographic partial response or stable disease on day 28, 1 of 10 patients with concurrently undetectable ctDNA relapsed; by contrast, 15 of 17 patients with concurrently detectable ctDNA relapsed (P = .0001). ctDNA was detected at or before radiographic relapse in 29 of 30 (94%) patients. All durably responding patients had undetectable ctDNA at or before 3 months after axi-cel infusion. CONCLUSION: Noninvasive ctDNA assessments can risk stratify and predict outcomes of patients undergoing axi-cel for the treatment of large B-cell lymphoma. These results provide a rationale for designing ctDNA-based risk-adaptive chimeric antigen receptor T-cell clinical trials.
PURPOSE: Although the majority of patients with relapsed or refractory large B-cell lymphoma respond to axicabtagene ciloleucel (axi-cel), only a minority of patients have durable remissions. This prospective multicenter study explored the prognostic value of circulating tumor DNA (ctDNA) before and after standard-of-care axi-cel for predicting patient outcomes. METHODS: Lymphoma-specific variable, diversity, and joining gene segments (VDJ) clonotype ctDNA sequences were frequently monitored via next-generation sequencing from the time of starting lymphodepleting chemotherapy until progression or 1 year after axi-cel infusion. We assessed the prognostic value of ctDNA to predict outcomes and axi-cel-related toxicity. RESULTS: A tumor clonotype was successfully detected in 69 of 72 (96%) enrolled patients. Higher pretreatment ctDNA concentrations were associated with progression after axi-cel infusion and developing cytokine release syndrome and/or immune effector cell-associated neurotoxicity syndrome. Twenty-three of 33 (70%) durably responding patients versus 4 of 31 (13%) progressing patients demonstrated nondetectable ctDNA 1 week after axi-cel infusion (P < .0001). At day 28, patients with detectable ctDNA compared with those with undetectable ctDNA had a median progression-free survival and OS of 3 months versus not reached (P < .0001) and 19 months versus not reached (P = .0080), respectively. In patients with a radiographic partial response or stable disease on day 28, 1 of 10 patients with concurrently undetectable ctDNA relapsed; by contrast, 15 of 17 patients with concurrently detectable ctDNA relapsed (P = .0001). ctDNA was detected at or before radiographic relapse in 29 of 30 (94%) patients. All durably responding patients had undetectable ctDNA at or before 3 months after axi-cel infusion. CONCLUSION: Noninvasive ctDNA assessments can risk stratify and predict outcomes of patients undergoing axi-cel for the treatment of large B-cell lymphoma. These results provide a rationale for designing ctDNA-based risk-adaptive chimeric antigen receptor T-cell clinical trials.
Authors: Zinaida Good; Jay Y Spiegel; Bita Sahaf; Meena B Malipatlolla; Zach J Ehlinger; Sreevidya Kurra; Moksha H Desai; Warren D Reynolds; Anita Wong Lin; Panayiotis Vandris; Fang Wu; Snehit Prabhu; Mark P Hamilton; John S Tamaresis; Paul J Hanson; Shabnum Patel; Steven A Feldman; Matthew J Frank; John H Baird; Lori Muffly; Gursharan K Claire; Juliana Craig; Katherine A Kong; Dhananjay Wagh; John Coller; Sean C Bendall; Robert J Tibshirani; Sylvia K Plevritis; David B Miklos; Crystal L Mackall Journal: Nat Med Date: 2022-09-12 Impact factor: 87.241
Authors: Ana Carolina Caballero; Laura Escribà-Garcia; Carmen Alvarez-Fernández; Javier Briones Journal: Front Immunol Date: 2022-07-06 Impact factor: 8.786
Authors: Rena R Xian; Tobias Kinyera; Isaac Otim; Joshua N Sampson; Hadijah Nabalende; Ismail D Legason; Jennifer Stone; Martin D Ogwang; Steven J Reynolds; Patrick Kerchan; Kishor Bhatia; James J Goedert; Sam M Mbulaiteye; Richard F Ambinder Journal: Front Oncol Date: 2021-12-14 Impact factor: 6.244
Authors: Andrea Kuhnl; Claire Roddie; Amy A Kirkwood; Tobias Menne; Maria Cuadrado; Maria A V Marzolini; Wendy Osborne; Robin Sanderson; Maeve O'Reilly; William Townsend; Reuben Benjamin; Victoria Potter; Piers E M Patten; Deborah Yallop; Stefan Voo; George S Petrides; Nicola Mulholland; Irfan Kayani Journal: Blood Adv Date: 2022-01-11
Authors: Elizabeth M Holland; Bonnie Yates; Alex Ling; Constance M Yuan; Hao-Wei Wang; Maryalice Stetler-Stevenson; Michael LaLoggia; John C Molina; Daniel A Lichtenstein; Daniel W Lee; John A Ligon; Haneen Shalabi; Mark A Ahlman; Nirali N Shah Journal: Blood Adv Date: 2022-04-12